AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
halothane 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| halogenated compounds used as general inhalation anaesthetics | 1356 | 151-67-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. NITROUS OXIDE is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required. (From AMA Drug Evaluations Annual, 1994, p178)
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK2,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT1,FLT3,GRK2,GSK3B,IGF1R,IKBKB,ITK,JAK1,JAK2,JAK3,KDR,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MARK4,MET,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM1,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 | 69 | |||
| kinase-selectivity-class | AXL,GRK2,PDK1,PDK2,PIK3CG | 5 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| March 12, 1958 | FDA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N01AB01 | NERVOUS SYSTEM ANESTHETICS ANESTHETICS, GENERAL Halogenated hydrocarbons |
| MeSH PA | D000777 | Anesthetics |
| MeSH PA | D002492 | Central Nervous System Depressants |
| MeSH PA | D018685 | Anesthetics, Inhalation |
| CHEBI has role | CHEBI:38870 | inhalation anaesthetic |
Related Drugs by ATC class:
N01AB Halogenated hydrocarbons 6 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| General anesthesia | indication | 50697003 | |
| Conduction disorder of the heart | contraindication | 44808001 | |
| Low blood pressure | contraindication | 45007003 | |
| Benign intracranial hypertension | contraindication | 68267002 | DOID:11459 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Malignant hyperthermia | contraindication | 405501007 |
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Multiple Species | Induction and maintenance of anesthesia | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Fluothane, Halothane, USP | Zoetis Inc. | 1 |
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Potassium channel subfamily K member 2 | Ion channel | OPENER | CHEMBL | CHEMBL | |||||
| Potassium channel subfamily K member 3 | Ion channel | OPENER | CHEMBL | CHEMBL | |||||
| Potassium channel subfamily K member 9 | Ion channel | OPENER | CHEMBL | CHEMBL | |||||
| Potassium channel subfamily K member 10 | Ion channel | OPENER | CHEMBL | CHEMBL | |||||
| Potassium channel subfamily K member 18 | Ion channel | OPENER | CHEMBL | CHEMBL | |||||
| Glycine receptor (alpha-1/beta) | Ion channel | POSITIVE MODULATOR | CHEMBL | CHEMBL | |||||
| GABA-A receptor; anion channel | Ion channel | POSITIVE ALLOSTERIC MODULATOR | CHEMBL | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4018499 | VUID |
| N0000146821 | NUI |
| D00542 | KEGG_DRUG |
| 4018499 | VANDF |
| C0018549 | UMLSCUI |
| CHEBI:5615 | CHEBI |
| CHEMBL931 | ChEMBL_ID |
| DB01159 | DRUGBANK_ID |
| D006221 | MESH_DESCRIPTOR_UI |
| 3562 | PUBCHEM_CID |
| 2401 | IUPHAR_LIGAND_ID |
| 697 | INN_ID |
| UQT9G45D1P | UNII |
| 1302180 | RXNORM |
| 4820 | MMSL |
| 55 | MMSL |
| 601 | MMSL |
| d00251 | MMSL |
| 001394 | NDDF |
| 387351001 | SNOMEDCT_US |
| 63682003 | SNOMEDCT_US |
Pharmaceutical products:
None